Höchster et al. showed that adding a MEK inhibitor to second-line irinotecan therapy in patients with KRASm CRC did not result in clinical benefit.22 However, patients with KRASm NSCLC had an improved response rate by the addition of the MEK inhibitor selumetinib to second-line treatment with docetaxel as reported by Jänne et al., although no significant effect on progression-free and overall survival was observed.5 The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.